POLYMED Poly Medicure Q4 FY26 results (Jan–Mar 2026) and concall
Poly Medicure reported a challenging but strategically transitional FY26, with stand-alone revenue growing 4% to INR1,662 crores and consolidated revenue up 12.3% to INR1,875 crores. Despite headwinds from raw material costs and logistics disruptions, the company achieved its EBITDA margin targets and made significant strides in high-technology verticals and international expansion, including a strategic acquisition in Brazil. Management is optimistic about reaccelerated growth in FY27, targeting 25% consolidated revenue growth and maintaining strong margins, while addressing ongoing market ch
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 21.3%, net profit down 29.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 420 | 424 | 441 | 403 | 444 +6% | 494 +17% | 535 +21% |
| EBITDA | 115 | 114 | 119 | 106 | 115 +0% | 111 −3% | 110 −8% |
| Net profit | 87 | 85 | 92 | 93 | 92 +6% | 71 −16% | 65 −29% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
